From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. by Gay, F et al.
From transplant to novel cellular therapies in multiple myeloma:
EMN guidelines and future perspectives
by Francesca Gay, Monika Engelhardt, Evangelos Terpos, Ralph Wäsch, Luisa Giaccone, 
Holger W. Auner, Jo Caers, Martin Gramatzki, Niels van de Donk, Stefania Oliva, 
Elena Zamagni, Laurent Garderet, Christian Straka, Roman Hajek, Heinz Ludwig, 
Hermann Einsele, Meletios Dimopoulos, Mario Boccadoro, Nicolaus Kröger, Michele Cavo,
Hartmut Goldschmidt, Benedetto Bruno and Pieter Sonneveld 
Haematologica 2017 [Epub ahead of print]
Citation: Francesca Gay, Monika Engelhardt, Evangelos Terpos, Ralph Wäsch, Luisa Giaccone, 
Holger W. Auner, Jo Caers, Martin Gramatzki, Niels van de Donk, Stefania Oliva, Elena Zamagni, 
Laurent Garderet, Christian Straka, Roman Hajek, Heinz Ludwig,  Hermann Einsele, Meletios Dimopoulos,
Mario Boccadoro, Nicolaus Kröger, Michele Cavo, Hartmut Goldschmidt, Benedetto Bruno
and Pieter Sonneveld. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines 
and future perspectives. Haematologica. 2017; 102:xxx
doi:10.3324/haematol.2017.174573
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on December 7, 2017, as doi:10.3324/haematol.2017.174573.
1 
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future 
perspectives 
 
Francesca Gay,1 Monika Engelhardt,2 Evangelos Terpos,3 Ralph Wäsch,2 Luisa Giaccone,4 Holger 
W. Auner,5 Jo Caers,6 Martin Gramatzki,7 Niels van de Donk,8 Stefania Oliva,1 Elena Zamagni,9 
Laurent Garderet,10 Christian Straka,11 Roman Hajek,12 Heinz Ludwig,13 Herman Einsele,14 
Meletios Dimopoulos,3 Mario Boccadoro,1 Nicolaus Kröger,15 Michele Cavo,9 Hartmut 
Goldschmidt,16 Benedetto Bruno,4* Pieter Sonneveld,17 
 
1 Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città 
della Salute e della Scienza di Torino, Torino, Italy; 2 UNIVERSITÄTSKLINIKUM FREIBURG, Medical 
Department, Hematology, Oncology & Stem cell transplantation, Freiburg, Germany; 3 Department of 
Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, 
Greece; 4 Department of Oncology, A.O.U Citta della Salute e della Scienza di Torino, and 
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; 5 
Centre for Haematology, Department of Medicine, Imperial College London, London, UK; 6 
Department of Clinical Hematology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire 
du Sart Tilman, Liège, Belgium; 7 Division of Stem Cell Transplantation and Immunotherapy, 2nd 
Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 8 
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands; 9 Seragnoli 
Institute of Hematology, Bologna University School.of Medicine, Bologna, Italy; 10 INSERM, UMR_S 
938, Proliferation and differentiation of stem cells, F-75012, Paris, France, AP-HP, Hôpital Saint 
Antoine, Département d'hématologie et de thérapie cellulaire, F-75012, Paris, France, Sorbonne 
Universités, UPMC Univ Paris 06; 11 Tumorzentrum München, Munich, Germany; 12 Department of 
Hematooncology, University hospital Ostrava, Ostrava, Czech Republic and Faculty of Medicine 
University of Ostrava, Ostrava, Czech Republik; 13 Wilhelminen Cancer Research Institute, c/o 
Department of Medicine I, Center of Oncology , Hematology and Palliative Care, Wilhelminenspital, 
11; 14 Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany; 15 
Department of Stem cell Transplantation, University Medical Center Hamburg-Eppendorf, Germany; 
16 Medizinische Klinik, Abteilung Innere Medizin V, Universitätsklinikum Heidelberg und National 
Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany; 17 Department of Hematology, 
Erasmus Medical Center, Rotterdam, Netherlands. 
 
RUNNING HEAD: transplant and cellular therapy in myeloma 
 
*Corresponding author: Benedetto Bruno, Department of Oncology, A.O.U Citta della Salute e della 
Scienza di Torino, and Department of Molecular Biotechnology and Health Sciences, University of 




Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation 
and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal 
antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-
dose melphalan followed by autologous transplantation significantly improves progression-free 
survival; although an overall survival benefit was not observed in all trials. Moreover, follow-up of 
recent trials is still too short to show any difference in survival. In the light of these findings, novel 
agent-based induction followed by autologous transplantation is considered the standard upfront 
treatment for eligible patients (level of evidence: 1A). Post-transplant consolidation and maintenance 
treatment can further improve patient outcome (1A). The availability of several novel agents has led to 
the development of multiple combination regimens as salvage treatment options. In this context, the 
role of salvage autologous transplantation and allotransplant have not been extensively evaluated. In 
case of prolonged remission after upfront autologous transplantation, another autologous 
transplantation at relapse can be considered (2B). Patients who experience early relapse and/or have 
high-risk features have a poor prognosis and may be considered as candidates for clinical trials that - 
in young and fit patients - may also include an allograft in combination with novel agents (2B). 
Ongoing studies are evaluating the role of novel cellular therapies, such as inclusion of antibody-
based triplets and quadruplets and Chimeric Antigen Receptor-T cells: despite preliminary 
encouraging results, longer follow-up and larger patient numbers are needed before their clinical use 




The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the 
last decades,1 with an improved median survival of 8-10 years. Multiple combinations of proteasome 
inhibitors (PIs) and immunomodulatory drugs (IMIDs) have been and are currently under evaluation in 
the transplant and non-transplant settings. Several pre-transplant inductions, and post-transplant 
novel agent-based consolidation/maintenance regimens have been investigated, although direct 
comparisons between such strategies have been rarely performed. ASCT is currently considered the 
standard of care for fit newly diagnosed MM (NDMM) patients, although remarkable results obtained in 
the non-transplant setting2,3 with novel agent-based treatment raised the question on the role of 
upfront vs delayed ASCT.  
The availability of second-generation PIs and IMIDs, monoclonal antibodies, histone deacetylase 
inhibitors, and, more recently, check-point inhibitors, and small molecules, has led to the development 
of multiple salvage options that include different permutations of these drugs. In this context, the role 
of salvage ASCT and allotransplant have not extensively been evaluated. These exciting advances 
require a critical review to delineate the merit of different induction, consolidation and maintenance 
approaches, as well as to define the role of upfront ASCT, salvage ASCT and allotransplant in the 
novel agent era. These important considerations prompted the EMN to provide guidelines to 
harmonize treatment selection. A brief overview of novel cellular therapies, which can somehow be 
considered the new frontier for transplant, are also provided. 
 
Methodology 
Clinical European Myeloma Network (EMN) experts on MM developed these recommendations based 
on published data through August 2017. Expert consensus was used to suggest recommendations in 
case of inconclusive data. Grades of recommendations were assigned using the GRADE criteria for 
grade of recommendation (Supplementary Table S1). The manuscript underwent revision in 3 rounds 
until the EMN experts reached mutual consent. 
 
 
Upfront Autologous Transplant 
The current treatment paradigm for NDMM patients eligible for ASCT consists of 4 phases, namely 
pre-transplant induction, transplant, post-transplant consolidation and maintenance.  
 
Pre-transplant Induction 
Induction treatment generally consists of 3-6 cycles with the goal to achieve rapid disease control, 
improve symptoms and allow for subsequent successful stem-cell collection. The current standard is a 
three-drug bortezomib-based combination. Doxorubicin-bortezomib-dexamethasone (PAD) proved to 
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be superior to standard chemotherapy in a randomized trial and,4 more recently, bortezomib-
cyclophosphamide-dexamethasone (VCD) was found to be non-inferior to PAD5. Improved responses 
were observed with combinations including both PIs and IMIDs. Indeed, CR rates were significantly 
higher with VTD compared with TD in 2 randomized trials (35% vs 14%, P=0.0001; 31% vs 11%, 
P<0.001).6,7 VTD vs VCD improved CR rates (13% vs 9% respectively).8 Higher CR rates were 
reported with bortezomib-dexamethasone plus the second-generation IMID lenalidomide (VRD) (23%-
48%) (Table 1).9,10 Direct, randomized comparisons of PAD vs VTD are lacking.  
Expected efficacy of a given regimen is one of the main factors to be considered in the treatment 
choice, the second factor being the expected toxicity. Infections are common events in NDMM, often 
to the underlying disease itself and to the treatment. The main issue with the use of bortezomib (in 
particular when combined with thalidomide) is the occurrence of peripheral neuropathy (PNP), which 
can be decreased substantially with subcutaneous and once-weekly administrations. The main 
concern with combinations including thalidomide or doxorubicin is the thromboembolic risk. Both PNP 
and thromboembolism appear lower when bortezomib is associated with cyclophosphamide (Table 2). 
Given that the benefit of bortezomib could be hampered by its neurological side effects, second 
generation PIs with minimal neurotoxicity demonstrated that induction treatment with ixazomib-
lenalidomide-dexamethasone (IRD) was very well tolerated (no grade 3-4 PNP, cardiac, liver or renal 
toxicities) and led to 12% CR rate.11 Carfilzomib-thalidomide-dexamethasone (KTd)12 or carfilzomib-
lenalidomide-dexamethasone (KRd)13 lead to 18-24% CR rate, although cardiovascular toxicities, 
(mainly hypertension) have been reported. 
The impact of depth of response on outcome14 provides the rationale for choosing the most effective 
induction regimen, provided the toxicity profile is acceptable. Nevertheless, only one randomized trial 
(Myeloma XI) investigated a response-adapted approach based on the sequential use of 
chemotherapeutic agents, with different modes of action in patients with a suboptimal response 
(minimal response/partial response) to thalidomide-based induction. Some 40% of patients upgraded 
their response with VCD before ASCT and significant improvement in PFS was observed (median 48 
vs 38 months, P<0.0001).15 Yet, the trial included suboptimal induction regimens (CTD and 
cyclophosphamide-lenalidomide-dexamethasone) not widely used outside the UK. The current 
standard of care is bortezomib plus IMIDs or chemotherapy, supported also by the results of two 
meta-analyses16,17 that showed the superiority of bortezomib- over non-bortezomib-
induction treatments. Thus, the impact of switching treatment - with currently much more effective 
induction regimens- still needs to be confirmed. 
 
Autologous Transplantation 
Several trials compared different chemotherapy regimens to standard high-dose melphalan 
(200mg/m2, MEL200), showing a favourable risk-benefit profile with MEL200 over Busulfan/Melphalan, 
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Idarubicin/Melphalan/Cyclophosphamide, BCNU/Etoposide/Melphalan, Melphalan 100/140 mg/m2. 
Conditioning regimens including novel agents have been evaluated so far only in single arm studies.18 
Given the efficacy and favorable toxicity profile of MEL200, this regimen remains the standard.  
Efficacy of novel-agent treatments in the non-transplant setting, together with a manageable safety 
profile and the advantage of the administration in the outpatient setting, questioned the role of 
MEL200-ASCT. Four randomized trials compared MEL200-ASCT vs novel agent-based triplets. In two 
trials, patients received Rd induction and were randomized to tandem MEL200-ASCT or oral 
lenalidomide-based chemotherapy (melphalan-prednisone-lenalidomide [MPR]/cyclophosphamide-
lenalidomide-dexamethasone [CRD]). Median PFS was significantly longer for patients randomized to 
tandem MEL200-ASCT than for those randomized to MPR (43 vs 22 months, P<0.001) or CRD (43 
months vs 28 months, P<0.001). Tandem ASCT also improved the 4-year OS rate vs MPR (82% vs 
65%, P=0.02) or CRD (86% vs 73%, P=0.004).19,20  
Two large studies compared MEL200-ASCT vs bortezomib-based regimens. MEL200-ASCT 
significantly prolonged PFS vs bortezomib-lenalidomide-dexamethasone (VRD)10 (median 50 vs 36 
months, P<0.001), and vs bortezomib-melphalan-prednisone (VMP)21 (3-year PFS 65% vs 57%, 
P=0.001). Follow-up of these two trials is still too short to show any differences in OS. 
Indeed, data confirmed that the toxicity profile was better and more manageable in the non-transplant 
arm, but no increase in toxic deaths was reported with MEL200-ASCT.10,19,20,21   
Before the introduction of novel agents, several studies showed a prolonged event-free survival (EFS) 
with double vs single ASCT.22 A subgroup analysis of one of those trials reported an improved OS 
only in patients achieving <VGPR after the first ASCT.23 A more recent integrated analysis of patient-
level data from 4 European trials demonstrated that, in patients receiving bortezomib-based induction, 
the greatest benefit with double vs single ASCT in terms of extended PFS (HR=0.41) and OS 
(HR=0.22) was seen in patients with t(4;14) and/or del(17p) and who failed CR to induction therapy.24 
Preliminary results of the EMN02 trial confirmed that patients receiving double ASCT have a superior 
PFS in comparison with patients randomized to a single ASCT (3-year PFS 74% vs 62%, P=0.05). 
The benefit was particularly evident in patients with high-risk cytogenetics (3-year PFS 65% vs 41%, 
HR 0.49, P=0.046).25  
On the contrary, the STAMINA trial showed no improvement in PFS in patients receiving double ASCT 
followed by maintenance vs single ASCT followed by VRD consolidation and lenalidomide 
maintenance. However, different induction, more effective and prolonged therapy with better disease 
control before ASCT, as well as non-adherence to the double ASCT policy in 30% of patients, can be 




Consolidation is a commonly adopted approach after transplant to improve depth of response. In 
“naïve” patients, bortezomib consolidation prolonged PFS vs no consolidation (median 27 vs 20 
months respectively; P=0.05), but no difference in OS was seen.27 In another trial, VTD consolidation 
increased the CR rate from 15% to 49% and the molecular remission rate from 3% to 18%.14 More 
recently, post ASCT consolidation with the same induction regimens was assessed. VTD increased 
the CR/nCR rate from 63% to 73%.28 Similarly, CR plus stringentCR rate increased from 47% to 50% 
after VRD.9 Preliminary results of the EMN-02 trial suggest that post-transplant VRD consolidation 
also prolongs PFS vs no consolidation (3-year PFS 65% vs 60% respectively, P=0.045);29 albeit the 
STAMINA trial did not find any improvement in PFS with single ASCT followed by VRD consolidation 
and lenalidomide maintenance vs single ASCT followed by lenalidomide maintenance; however, the 
rate of non-compliance to VRD was sizeable with 12%.26 
Similarly to induction phase, combining second-generation PIs and IMIDs is advantageous also in the 
consolidation phase, enhancing CR rates from 20% to 32% with IRD, from 31% to 64% with KTd, from 
45% to around 70% with KRD.11–13 
 
Maintenance regimens 
The optimal maintenance regimen should aim at prolonging the remission duration without affecting 
patients' quality of life. Although meta-analyses showed a reduced risk of progression (HR=0.65) and 
death (HR=0.84) with thalidomide maintenance, in the IFM and MRC IX studies, patients with 
unfavorable cytogenetics did not benefit from this approach.30,31 In addition, grade 3-4 PNP (7-19%) 
and treatment discontinuation due to PNP limit the long-term use of thalidomide. 
Bortezomib maintenance seems to be a better option: a landmark analysis of the HOVON-65/GMMG-
HD4 trial showed that bortezomib maintenance significantly reduced the risk of progression (P=0.04) 
and death (P=0.05) as compared with thalidomide, with a similar rate of grade 3-4 PNP (5% vs 8%).4 
Results of this trial also suggest that pre-transplant bortezomib induction followed by bortezomib 
maintenance significantly reduces the high-risk impact of del(17p) and renal impairment on survival.32 
More recently, longer PFS was reported also with the bortezomib-thalidomide combination vs 
thalidomide alone.33 
Lenalidomide is another valid strategy for long-term treatment, with limited neurotoxicity: 4 trials 
subsequently evaluated lenalidomide maintenance after ASCT,19,34–36 showing a consistent PFS 
benefit for lenalidomide vs no maintenance (HR range 0.46-0.50). A meta-analysis of the first three 
randomized trials reported a significant increase also in OS (7-year OS 62% vs 50%, HR 0.75; 
P=.001) across all subgroups analyzed with the exception of patients with high-risk cytogenetics. In 
the MRC trial, a significant PFS benefit was maintained also in patients with high-risk cytogenetics, but 
no data on OS are currently available. Main grade 3-4 toxicities were neutropenia (23-51%), and 
infections (6-13%).19,34,35 Although second primary malignancies (SPMs) were higher with 
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lenalidomide maintenance vs control (hematologic SPM, 6.1% vs 2.8%; solid tumor SPM, 7.3% vs 
4.2%),37 the OS benefit outweighed the SPM risk.  
Recommendations: In NDMM patients eligible for high-dose therapy and ASCT, sequential treatment 
including novel agent-based induction, upfront transplant, post-transplant bortezomib plus IMiDs 
consolidation and maintenance is recommended (1A; Figure 1). Treatment choice should be based on 
evidence supporting a specific treatment, and on a thorough evaluation of patient characteristics, 
toxicity of the expected regimens and availability of drugs in the specific countries (Table 3).  
 
Special considerations 
Currently, selection criteria for high-dose therapy include age and comorbidities. However, a definite 
age cut off is suboptimal, rather than assessment of patients’ biological age, comorbidities, fitness and 
frailty/comorbidity scores. Besides age, the performance status, cardiac, pulmonary, hepatic and renal 
functions should be considered to better evaluate the risk-benefit ratio of transplant for each patient, 
and specific risk-assessment models, such as myeloma comorbidity index (MCI) and/or Hematopoietic 
cell transplantation comorbidity index (HCT-CI) should be used to better modulate the dose of 
chemotherapy.38–40 Specific considerations refer to patients with renal failure (RF) and elderly patients.  
 
Renal failure (RF) 
Around 20% of patients present at diagnosis with creatinine >2mg/dL. Bortezomib-based regimens 
remain the cornerstone for the management of RF. Indeed, higher response rates were reported with 
PAD vs VAD induction in patients with RF (81% vs 63%, p=0.31).41 In dialysis patients, bortezomib-
based induction vs conventional chemotherapy significantly increased pre-transplant (83% vs 36%, P= 
0.02) and post-transplant overall response rate (100% vs 58%, P=0.01). Prolonged EFS and a trend 
towards a decreased time on hemodialysis (6 vs 17 months) was also reported.42 Combination of 
bortezomib with high cut-off hemodialysis led to prompt and remarkable responses.43 RF does not 
appear to affect the quality of stem cell collection.44 Persistent RF or dialysis are not contraindications 
to high-dose therapy and ASCT,45 since patients may improve renal function after ASCT. 
Nevertheless, the rate of treatment-related mortality (TRM) ranges from 0 to 29% in different reports 
and with different melphalan doses.42,44 Thus, due to the potentially higher toxicity of 200mg/m2, dose 
reductions are mandatory particularly in dialysis patients. Other suggested reductions in case of 
impaired organ function are reported in Supplementary Table S2. Of note, a recent large retrospective 
analysis showed no significant differences in the 5-year PFS and OS between transplant patients with 
normal, moderate (GFR 30-60 ml/min/1.73 m2) and severe RF (GFR <30). For patients with moderate 
RF, 5-year PFS was 18% with melphalan 140mg/m2, and 46% with melphalan 200mg/m2 (p=0.009); 5-
year OS was 67% and 68%, respectively (p=0.52). In patients with severe RF (GFR <30) no 
differences in 5-year PFS and OS were reported between groups. Relapse remained the primary 
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cause of death in all patient subgroups.46 In this report, 85% patients achieved dialysis independence 
post-ASCT even though, in previous case-series, rate of dialysis independency varied from 6 to 
25%.44 
Of interest, around 10% of younger patients may achieve long-lasting responses, which makes them 
potential candidates for renal transplantation. However, many issues, including donor availability, the 
immunosuppression risks and the possible disease relapse on the xenograft, need to be considered. 
Thus, patients with low-risk disease and with negative MRD might be considered eligible for 
transplantation in the future but currently, due to limited data, no recommendations can be made.44 
 
Transplant in the elderly 
Aging is associated with reduced organ function and drug metabolism, with potentially increased 
toxicity and TRM. The potential increase in toxicity has led to the evaluation of reduced doses of 
melphalan (100-140mg/m2) conditioning. Many studies, mostly retrospective, observational or registry-
based, provided encouraging results with ASCT in patients >65 years, with TRM <3-4%.47 No 
differences in TRM (1%) were reported with tandem melphalan 140mg/m2 in patients aged 60-65 vs 
65-70 in the large DSMM II trial.48 Interestingly, a recent study found that ASCT-TRM was 0% with 
either melphalan 140mg/m2 or 200mg/m2, which may partly be due to improvements in supportive 
therapy and better patient selection.49 A recent EBMT study confirms increased utilization and safety 
of ASCT with improved post-transplant survival, particularly in elderly MM patients.50 
Former analysis of non-ASCT treatment vs ASCT in the elderly (65-75 years) compared thalidomide 
based chemotherapy (MPT) vs reduced-intensity (melphalan 100mg/m2) ASCT in patients aged 65-75 
years in the IFM9906 trial. MPT significantly reduced the risk of progression (HR 0.54, P=0.0002)51 
and death (HR 0.69; P=0.027), but the lack of novel agents in the pre-ASCT induction and the low 
melphalan dosing can be a limitation to the study. The rate of toxic deaths was also higher (5%) during 
induction in the ASCT arm. Afterwards, other prospective trials evaluated a sequential approach 
including novel agent based induction, consolidation and maintenance. One study showed that PAD 
induction, followed by MEL100-ASCT, lenalidomide-prednisone consolidation and lenalidomide 
maintenance was highly efficacious (VGPR rate 82%; 5-year OS 63%) and feasible, in particular for 
patients <70 years, who reported a significantly lower rate of TRM in comparison with elderly patients 
(5% vs 19%).52 A recent report suggests that bortezomib consolidation after ASCT may determine 
clinical outcomes in older patients, who may have been less heavily pre-treated, as in younger ones 
treated with standard doses of melphalan.53 The phase III DSMM XIII trial compared continuous Rd vs 
Rd induction followed by tandem melphalan 140mg/m2-ASCT and lenalidomide maintenance. Results 
of the planned interim analysis showed a 3-year-survival rate of 75% for all patients. A longer follow-
up is needed to evaluate the potential advantages and disadvantages of combining lenalidomide with 
high-dose melphalan-ASCT as compared with continuous Rd.54 
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Recommendations: Biological age rather than chronological age, PS, and organ function should be 
considered to better evaluate the risk-benefit ratio of transplant for each patient (1B, Figure 2). 
Objective risk-assessment scores, such as revised-myeloma comorbidity index (R-MCI) and/or 
Hematopoietic cell transplantation comorbidity index (HCT-CI) can be used to define the appropriate 
dose of chemotherapy38–40 (1B, Table 4). 
 
Transplant at relapse 
Upfront vs rescue transplant 
In the past, several randomized trials confirmed the PFS benefit with early ASCT as compared with 
chemotherapy. In three randomized studies, OS was similar whether ASCT was performed early or at 
first relapse. Despite similar OS, early ASCT improved the average time without symptoms and 
reduced treatment-related toxicities in one trial.55 However, at the time of these trials, most novel 
agents were not available. Based on the impressive results of novel agent-based treatments in the 
non-transplant setting, the option of delaying ASCT until first relapse was again reconsidered.2,3,56 In 
all the recent randomized phase III trial comparing ASCT vs novel agent-based therapies, patients 
who did not receive ASCT upfront were recommended to receive it at first relapse. A pooled analysis 
including the GIMEMA and the EMN441 trials showed that only 53% of patients eligible for Mel200-
ASCT at diagnosis actually received ASCT at first relapse. Upfront MEL200-ASCT significantly 
improved not only PFS1, but also PFS2 (4-year: 71% vs 54%, HR 0.53, p<0.001) and OS (4-year: 
84% vs 70%, HR 0.51, P<0.001) as compared with oral chemotherapy plus lenalidomide.57 Of note, in 
the IFM2009 trial, where up to 79% of patients treated with lenalidomide plus bortezomib upfront were 
rescued with ASCT at relapse, no differences in OS were noticed.10  
 
Transplant in patients relapsing after prior autograft 
Multiple retrospective analyses showed that chemo-sensitivity and remission duration after first ASCT 
are the most important prognostic factors for long-term disease control after salvage ASCT.58,59 Most 
reports also highlighted the impact of the number of prior therapies on outcome, suggesting that 
salvage ASCT should be part of the initial salvage strategies, rather than be offered to patients who 
have failed multiple therapy lines. A retrospective analysis on 1061 patients showed a significantly 
longer median survival for patients who received salvage ASCT (4 years) vs those who received 
salvage IMIDs/PIs and no ASCT (3.3 years), and those who received conventional chemotherapy (2.5 
years).60 A limitation of this analysis is a possible selection bias as patients treated with ASCT may 
have been in better clinical condition if compared with those who did not. Nevertheless, the phase III 
multicenter randomized Myeloma X trial showed a significant advantage in time to progression (19 vs 
11 months, P<0.001) and OS (67 vs 52 months, p=0.022) in patients relapsing after a previous ASCT, 
and then randomized to receive either a second ASCT or oral cyclophosphamide.61 The limitation of 
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this trials however is that, even though all patients were re-induced with PAD prior to randomization, 
the control arm with cyclophosphamide alone can now be considered suboptimal. A recent 
retrospective EBMT analysis showed that even a third ASCT at relapse may be feasible, with more 
than 80% of patients achieving at least a PR, although with increased non-relapse mortality. 
Particularly in severely cytopenic patients where hematologic toxicity of conventional treatment may 
be prohibitive, ASCT may be a rescue option. The option of a third ASCT mostly followed a previous 
upfront approach with tandem ASCT; some patients received a first ASCT followed by a second ASCT 
at second relapse and a third ASCT at subsequent relapse. The first scenario resulted in better results 
with a median OS of more than 4 years if the relapse occurred after more than 3 years after the 
upfront tandem ASCT.62  
Recommendations: Upfront ASCT remains the standard option for patients eligible for HDT (1A, 
Figure 1). A second transplant at relapse should be considered after a minimal duration of remission 
of 18 months after a first ASCT (1B); this cut-off could be extended to 24 months in the context of 
novel induction/maintenance.63 A second ASCT should be offered as a first salvage therapy rather 
than after failing multiple lines (2B). Novel-agent based induction and consolidation-maintenance 
should be adopted also in the elderly (1A). 
 
Allotransplant 
When and in which patients 
A review of approximately 3000 ASCTs and allo-SCTs, performed in the US between 2007 and 2009, 
showed that, overall, 47.1% of ASCTs and only 3.6% of allo-SCTs were performed in MM patients.64 
However, the number of allo-SCTs for MM in Europe steadily increased from 1990 to 2012.65 Before 
new drugs became readily available almost 20 years ago, in a series of "biologically" randomized 
prospective studies, the concept of splitting myeloablation and graft-vs-myeloma (GVM) by a tandem 
approach with a standard ASCT followed by a non-myeloablative allo-SCT, from a matched sibling or 
an unrelated donor, was explored in NDMM (Table 5).66–76 Results were discordant, and this was likely 
due to differences in study design, target population and post-transplant immuno-suppression (Table 
3). Moreover, only at long-term follow-up differences in clinical outcomes between arms were 
observed.73,74. Of note, at that time, most studies could not include new drugs either at induction or as 
post allo-SCT maintenance/consolidation. 
Partly due to the conflicting results and to the introduction of new drugs, allo-SCT has rather been 
used in recent years as a salvage strategy at relapse, often not in the context of clinical trials. Most 
reports were single-institution or registry analyses. Only a few comparative studies have been 
conducted, and those are limited by their retrospective nature and/or small patient cohorts (Table 6). In 
a recent EBMT report65 on 7333 MM patients who underwent allo-SCT between 1990 and 2012, 3405 
had received allo-SCT as a second line or beyond regimen: this report showed that 25% of the patient 
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cohort who received allo-SCT more than 8 months from the first ASCT survived at 10 years, 
suggesting that cure may have been reached through a GVM mechanism in some patients. Another 
retrospective EBMT analysis identified patient and donor CMV seronegativity as the key prognostic 
factor for better outcome after allo-SCT in relapsed patients.77 One prospective study78 concluded that, 
with well-matched donors, the non-relapse mortality was 10%, and about 20% of patients achieved 
long-term disease free survival. The high response rates seen after DLI administration are additional 
evidence for the GVM. 
All together, these studies showed the feasibility of allo-SCT in relapsed MM; however, given the 
heterogeneous patient cohorts and differences in conditioning regimens and supportive care, its real 
role and curative potential has not been clearly established. Both reduced-intensity and myeloablative 
conditionings have been successfully used, and so far, the choice should be based on center policy 
and patients comorbidities. 
Considering the lack of effective therapy for high-risk patients carrying del(17p), gain(1q), t(4;14) and 
t(14;16) abnormalities, new treatment modalities should be sought in this patient subset. The negative 
prognostic impact of high-risk cytogenetics appeared to be partly neutralized by GVM in two recent 
studies. Kröger et al. did not observe significant differences in PFS between del17p13 and/or t(4;14)-
harboring patients and those without these genetic abnormalities after a median follow-up of 6 years 
(24% vs 30%; P=0.70). Depth of remission had a remarkable impact on 5-year PFS: 17% for PR, 41% 
for CR, 57% for molecular CR, and 85% for sustained molecular CR.79 A French trial also showed no 
differences in clinical outcomes between t(4;14) and non-t(4;14) patients. Moreover, the 3-year 
progression rate did not exceed 45% in patient with del(17p).80 Taken together, these findings raise the 
question whether high-risk patients who usually experience poor outcomes and easily develop 
resistance to novel agents would benefit from allo-SCT earlier in the course of the disease. 
 
Evidence of graft vs myeloma 
Response to DLIs is often seen as proof of GVM. However, the prolonged post-relapse survival 
reported after tandem auto-allo-SCT upfront suggests an important synergy between novel agents and 
GVM.73,74 In several reports, DLIs have been used as salvage treatment. Beitinjaneh et al.81 reported 
on 23/162 patients with MM receiving DLI post allo-SCT for residual or relapsed disease: 22% 
achieved >VGPR, with a median duration of 21.8 months. Similarly, an analysis of EBMT registry data 
reported a response rate of 63% in 70 patients when DLI was given preemptively and 52% when given 
at relapse.82 Ladetto et al. reported a gradual reduction of residual disease with longer follow up. 
Minimal residual disease negativity, detected by molecular methods, remained low up to 3 months 
post alloSCT, then increased up to 44% at 6 and 47% at 12 months.83 Importantly, these patients did 
not receive any maintenance/consolidation treatment. These findings also compared favorably with 
the molecular analysis conducted by the same group in patients undergoing autografting and VTD 
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consolidation.14 Finally, although not univocal, many trials reported a favorable association between 
development of chronic GVHD and prolonged PFS and OS,84,85 again supporting a GVM effect. 
 
Novel agents and graft-vs-myeloma 
Although the introduction of “new drugs” has made allografting a less attractive treatment option 
because of its toxicity, the mechanisms of action of new drugs and immune-mediated GVM effects are 
by no means mutually exclusive.73,74 Given that one of the most important predictors of survival is the 
response at the time of transplant and the major limitation remains disease recurrence as for all other 
treatments, the new anti-MM drugs may strongly improve outcomes of allo-SCT. Moreover, the 
concept of maintenance treatment was also recently introduced in the setting of allografting. 
Bortezomib has been used before allo-SCT and early after allo-SCT to eliminate residual disease and 
to decrease graft-vs-host disease (GVHD) incidence and severity based on its presumed 
immunomodulator potency in at least two prospective studies86,87 on 16 and 12 high-risk MM patients, 
respectively. Both trials proved feasible and safe, and, based on these results, the expert panel agrees 
that confirmatory larger studies should be designed. 
Lenalidomide is also of interest in the allo-SCT setting though caution is mandatory because of the 
risk of GVHD flares if given too shortly after transplant. Three trials86,88,89 demonstrated that post allo-
SCT lenalidomide maintenance was feasible and contributed to further reduce MM tumor burden with 
PFS rates of 52% at 3 years;88 63% at 3 years,89 and 60% at 2 years90. GVHD flares were observed in 
28% to 47% of cases. 
 
Update on current studies 
At the 2016 American Society of Hematology meeting (December 2016), reports on myeloma and allo-
SCT mainly focused on interactions of new drugs and GVM, and three groups unanimously reported 
remarkable responses to new drugs used as post-allo-SCT salvage, clearly showing a synergism with 
GVM. A retrospective study comparing OS after relapse from upfront auto-allo (n=178) vs double auto-
SCT (n=404) was conducted through the CIBMTR (Center for International Blood and Marrow 
Transplant Research) registry.91 Despite a higher risk population (46% of early relapse from 2nd SCT 
vs 26%) in the allo-SCT group, long-term reduction in post-relapse mortality (HR for death in auto-
auto-SCT=1.55; p=0.0052) was observed. This was clearly attributable to improved response to 
salvage therapy due to the donor derived immunologic milieu that potentiated the immune effects of 
new agents. Similarly, Giaccone et al showed prolonged OS from 1st relapse post tandem auto-allo-
SCT compared to double auto-SCT (89.8 months vs 23.5 months, p=0.009).92 López-Corral et al 
reported similar pre-transplant and post-transplant response rates and durability of response achieved 
with new drugs before and after allo-SCT: responses post allo-SCT were at least similar in proportion 
and durability to those observed in the pre-transplant setting, which is in contrast to the usual course 
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of the disease outside the allo-SCT setting.93 Another study reported on 18 high-risk MM patients who 
received upfront auto-SCT followed by RIC allo-SCT and bortezomib as maintenance, which was 
overall well tolerated, although 4/18 had asymptomatic EBV reactivation. Depth of response improved 
after bortezomib, with 67% of patients in CR or stringent CR.94 
Daratumumab has also demonstrated encouraging efficacy in 10 heavily pretreated 
relapsed/refractory patients after allo-SCT. Safety profile was good with in the majority of cases non-
severe AEs mostly after the first infusion; 5/9 evaluable patients responded and all responding 
patients maintained their responses 7, 14, 35, 54 and 84 days after the first administration.95 Cook et 
al monitored immune biomarkers with the use of lenalidomide after T depleted RIC-alloSCT, showing 
that the agent allowed sustained quantitative and functional reconstitution of donor immune 
homeostasis.96 McKiernan et al97 reported of a long-term comparison in patients receiving allo-SCT as 
upfront consolidation (n=75) or as salvage therapy (n=43). The 10-year OS for patients who received 
allo-SCT as salvage was 36% vs 68% for the consolidation group (p=0.0007). Of note, having 
undergone ≥2 prior auto-SCTs predicted for a higher risk of mortality (p=0.05). Chronic GVHD was 
favorable, associated with a 36% improvement in OS (p=0.0008).  
Recommendations: Previous studies that did not include novel agents reported long-term molecular 
remissions, and possibly cure, in patient subsets. Well-designed prospective trials combining “graft-
vs.-myeloma” and new drugs may become urgent in young high-risk/ultra high-risk patients whose 
treatment remains an unmet clinical need. However, there are no current data that support an upfront 
allograft. A clinical indication/recommendation may also become “early relapse” after first-line 
treatment (including the new PI and IMIDs) which identifies patients at very poor prognosis 
independent of other prognostic factors (Table 7). Re-induction to obtain tumor shrinking using novel 
drugs as bridge to transplant is highly recommended/mandatory in this setting.98 Novel agent-based 




Treatment for MM has undergone a dramatic improvement in the past decade given the considerable 
advances in the understanding of the disease pathogenesis and numerous novel drugs and 
combinations being approved for the disease. Despite the development of novel agents which target 
not only MM cells but also the microenvironment,99 the prognosis of patients with early 
relapsed/refractory MM remains poor. Thus, new therapeutic modalities are urgently needed to 
overcome resistance to current therapies. Several immunotherapies have recently been proposed, 
which - among others - include monoclonal antibodies, antibody-drug conjugates, chimeric antigen 
receptor T-cell therapy (CAR-T cells), tumor vaccines and immune checkpoint inhibitors.100 Preliminary 
results observed in patients with B cell hematologic malignancies with infusion of T cells genetically 
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modified to express synthetic chimeric antigen receptors (CARs) against the lineage-specific surface 
antigen CD19 were impressive. T cells engineered with an anti-CD19 CAR induced CR also in a 
patient with MM.101 Recently, a number of other CAR-T cells have been designed to target surface 
antigens expressed by MM cells and include CD38,102 CD138,103 CD269, the B cell maturation antigen 
(BCMA),104 κ light chains,105 CS1 (CD319)106 and CD44v6.107 However, despite their efficacy, CAR-T 
cells have raised many concerns on their short- and long-term toxicities, in particular the development 
of life-threatening cytokine release syndrome (CRS) and prolonged aplasia of the healthy 
counterparts.108 Genetic modifications of cells belonging to the innate immune system such as natural 
killer (NK) cells are also being explored, and modification of the human NK cell lines NKL and NK-92 
with a lentiviral vector encoding for CS1 and CD138 CARs has proven feasible.109 However, several 
steps to optimize and validate CAR-modified NK cells have to be undertaken before their wider clinical 
use becomes feasible. 
 
Conclusions  
The changes in the treatment paradigm for MM patients in the last two decades dramatically improved 
survival. Clearly, results of the most recently published trials confirm the role of ASCT in the era of 
novel agents, with new drugs administered both in the pre-transplant and post-transplant phases. The 
expert panel emphasizes that present clinical research should balance between treatment efficacy and 
quality of life, identify the optimal sequencing of treatment, the appropriate tools for patient selection, 
evaluate costs of prolonged novel-agent application vs transplant remission efficacy, treatment-free 
intervals, and it should understand how to best induce long-term remission.110 In the future, objective, 
prospective and proficiently performed fitness tools may prove to be of benefit before intensive 
treatment is started, especially since fitness assessments made by patients and physicians are not as 
objective as fitness evaluations derived from well-defined tests and scores. Future randomized studies 
will also need to evaluate the role of ASCT as salvage treatment in the context of the novel 
combinations currently available as salvage options. 
The trend in survival improvement is likely to continue in the future with new classes of drugs (such as 
MoAb) and second-generation PIs and IMIDs moving in the upfront setting. If most patients can now 
expect a long-term disease control, the optimal definition of high-risk disease and the specific 
treatment for these patients remains a major challenge. Based on the available data, the opinion of the 
expert committee is that allotransplant in combination with novel agents might be considered in the 
context of clinical trials for high-risk patients who are willing to accept the TRM for a chance of a better 
long-term survival. Moreover, cellular therapies, now still highly experimental, should be optimized, 
made broader available and payable to be included in our treatment armamentarium. 
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TABLE 1. EFFICACY OF SEQUENTIAL APPROACHES WITH AUTOLOGOUS TRANSPLANTATION: IMPROVEMENT IN RESPONSE RATES, 
PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL WITH SEQUENTIAL INDUCTION, TRANSPLANT, AND CONSOLIDATION-
MAINTENANCE REGIMENS 
REGIMEN N of 
patients 












50% at 35 months 
 














60% at 36 months* 
 














50% at 56 months 
 
















50% at 50 months 
 
















65% at 36 months 
 






























83% at 20 months 
 




Abbreviations: CR, complete response; MEL 200: melphalan 200 mg/m2,; PFS, progression-free survival; OS, overall survival; FU: follow-up; R, lenalidomide; RP, lenalidomide-prednisone; T, 
thalidomide; V, bortezomib; VTD, bortezomib-thalidomide-dexamethasone;; PAD, bortezomib-adriamycin-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-
cyclophosphamide-dexamethasone; KRD, carfilzomib-lenalidomide-dexamethasone; IRD, ixazomib-lenalidomide-dexamethasone; -, data not available ; °response to the overall treatment,*PFS/OS from 




























PAD 3 10 8 4 24 26 4 
VTD 10 8 - 12 14 21 6 
VCD 35° 4 6 3# 8# 22# 5 
KRD 16 2 2 - - 15 13 
CONSOLIDATION 
VTD - 5* - 1 1 1 28 
KRD 26 15 - - - 2 13 
MAINTENANCE 
V  0 4 1 1 5 24 4 
T 1-16 2 1 1 8-14 18 4,33 
R  23-51 4-14 2-5 2-3 1 6-8 19,20,34,35 
TV 13 10 - - 15 - 33 
Abbreviations: R, lenalidomide; T, thalidomide; V, bortezomib;  VTD, bortezomib-thalidomide-dexamethasone; PAD, bortezomib-adryamicin-dexamethason; VRD, bortezomib-
lenalidomide-dexamethasone; VCD, bortezomib-cyclophosfamide-dexamethasone; KRD, carfilzomib-lenalidomide-dexamethasone; IRD, ixazomib-lenalidomide-dexamethasone; 
RD, lenalidomide-dexamethasone; TV, thalidomide-bortezomib; PNP: peripheral neuropathy; °including leukopenia; #≥grade 2; * all grade events;  -  Data not available 
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Table 3. RECOMMENDATIONS FOR UPFRONT TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS. 
 Regimens Recommendation Rationale for recommendation 
Induction VTD (1A) 
VRD (1B) 
PAD (1A) 






in pts with PNP 
- Non-thrombotic agents 
(cyclophosphamide) to be 
considered in pts with 
thrombosis  
- Lenalidomide use is 
supported by better toxicity 
profile than thalidomide, and 
the advantage of an oral use 
as compared with doxorubicin. 
 
Number of cycles: 
- treatment should be 
continued for at least 3-4 
cycles with all regimens 
- patients achieving >PR with 




- Randomized comparisons showing the superiority of one of these regimens over 
the others are lacking. 
- Treatment choice should consider patient characteristics and expected toxicity of 
the proposed regimens. 
- VTD showed superiority vs TD, chemotherapy without novel agents and VCD.6,7,8 
- VRD showed promising phase II and III efficacy results, with a good safety profile, 






Number of cycles: 
- Most of the trials evaluated 3-4 cycles of induction 
- Phase III data on efficacy and toxicities of > 4 cycles are lacking, except for VTD. 
4,5,6,7,8
  
- Randomized comparison of prolonged induction until best response and ASCT vs 
fixed duration of induction and ASCT are lacking  





Number of cycles: 
2 MEL200-ASCT are 
recommended in particular in 






1 MEL200-ASCT can be 
considered for standard risk 
patients achieving >VGPR 
Treatment choice: 
- Randomized trials showed a favourable efficacy and safety profile of MEL200 vs 
other regimens (Bu/Mel, Ida/Mel/Cy, BCNU/Etoposide/Mel, Mel100, Mel140).18 
- Novel agents in the conditioning regimens were evaluated so far only in single arm 
studies. 18 
 
Number of cycles: 
- Data from meta-analysis and 2 phase III trials  suggest that the greatest benefit 
with double vs single ASCT is for patients with high-risk disease.4,24,25 Phase III data 
of STAMINA trial, showed equal PFS between patients that, after a first ASCT, were 
randomized to consolidation with a second ASCT plus lenalidomide maintenance, or 
VRD consolidation -followed by maintenance or maintenance only, but these results 
may be affected by non-adherence to the second transplant policy in 30% of 
patients. maintenance4,26 
 
- Integrated patient level meta-analysis in the context of bortezomib induction 
showed the greatest benefit for double vs single ASCT in patients who failed CR to 
27 
induction therapy. Before novel agent treatment, the benefit of double ASCT was 
reported in patients achieving <VGPR after the first ASCT.23 
Consolidation VTD (2A) 
VRD (2A) 
Treatment choice: 
- Lenalidomide use is 
supported by a better toxicity 
profile than thalidomide 
- Lenalidomide should be 
preferred in pts with PNP 
 
 
Duration of therapy: 
- 2 VTD cycles  
 
- 2 VRD cycles 
 
Treatment choice: 
- Randomized comparisons showing the superiority of one of the regimens over the 
other are lacking. 
- Treatment choice should consider patient characteristics and expected toxicity of 




Duration of therapy: 
- A randomized trial showed the superiority of 2 VTD vs 2 TD consolidation in terms 
of response rate and PFS7 
- Preliminary data of a randomized trial showed the superiority of 2 VRD cycles vs 







- Lenalidomide use is 
supported by a better toxicity 
profile than thalidomide, 
which favours the long-term 
administration   
- Bortezomib use is supported 
by a better toxicity profile 
than thalidomide, and a 
potentially higher efficacy 
- IMIDs alone could be 
suboptimal in high-risk 
patients and patients with 
renal failure, who may benefit 
from bortezomib  
 
Duration of therapy: 
- Lenalidomide: at least 2 
years or until tolerated 
- Thalidomide: until tolerated 
- Bortezomib: 2 years 
Treatment choice: 
- Treatment choice should consider patient characteristics and expected toxicity of 
the proposed regimen 
- Thalidomide and lenalidomide maintenance have been evaluated in several 
trials19,30,31,34,35 
- One study showed the superiority of bortezomib over thalidomide maintenance, 
but results are limited by the fact that patients receiving bortezomib maintenance 
received bortezomib induction, while patients randomized to thalidomide received 
VAD 4 
- Randomized comparisons showing the superiority of lenalidomide vs 
thalidomide/bortezomib are lacking. 
- Subgroup analyses of randomized trials showed an uncertain benefit of IMiDs in 




Duration of therapy: 
- there is no randomized trials comparing 2 years of lenalidomide vs lenalidomide 
until PD, but the median duration of maintenance is around 2 years in most of the 
trials 
- long term thalidomide use is limited by the poor tolerance (PNP) 
- bortezomib maintenance have been administered in clinical trials for up to 2 
years 
 
Abbreviations : MEL 200: melphalan 200 mg/m2,; ASCT, autologous stem cell transplant ; PFS, progression-free survival; OS, overall survival; VTD, bortezomib-thalidomide-dexamethasone;; PAD, 
bortezomib-adriamycin-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone; VAD, vincristine-doxorubicine-dexamethasone PNP, 
peropheral neuropathy ; IMiD, immunomodualtory drugs. 
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Table 4. RECOMMENDATIONS FOR TRANSPLANT IN ELDERLY PATIENTS AND PATIENTS WITH CO-MORBIDITIES. ALL 





Recommendation Rationale for recommendation 
Age <65 years - Age should be considered not as single factor but 
together with Performance Status and co-morbidities 
(HCT-CI/MCI) 
- Biological rather than chronological age should be 
used in deciding eligibility to ASCT. 
- In patients between 65-70 years, with Karnofsky 
PS>90% and HCT-CI = 0 or R-MCI 0-3, it is reasonable 
to consider full dose Melphalan (200 mg/m2) 
- Based on biological age, melphalan dose reductions 
(Melphalan 100-140 mg/m2) can be appropriate. 
- Retrospective data showed in recent years no increase in 
TRM in elderly patients, probably due to better supportive 
measures and patient selection. These results have been 
achieved not only with reduced dose of Melphalan, but 
also with full dose.50–53,55–57 
Performance 
Status 
Karnofsky>90% - In patients with Karnofsky PS <90% Melphalan dose 
reductions (Melphalan 100-140 mg/m2) should be 
considered. 
 
- Full dose Melphalan (200 mg/mq) could be 
considered in patients with poor PS related to the MM, 
more than to other co-morbidities 
- Retrospective analysis of registry data showed an inferior 
OS in patients with Karnofsky PS<90%.41 
 
- Poor PS can be related to MM (i.e. bone disease, and rib 
and vertebral fractures that affect respiratory function, 
suboptimal response of MM to previous therapy can lead to 
anemia and fatigue). Achieving optimal disease control can 
improve patient PS.  
Co-
morbidities 
HCT-CI = 0 
R-MCI 0-3 
- In patients with HCT-CI >1 or R-MCI 4-6 Melphalan 
dose reductions (Melphalan 100-140 mg/m2) need to 
be considered. 
Specifically, in case of impaired:   
a) cardiac function (LVEF 40-50%; NYHA II) 
b) liver function (bilirubin >1.5 ULN, AST/ALT 
>2.5 ULN) 
c) pulmonary function (DLCO/FEV1 40-80%) 
d) renal function (GFR <60) 
but, in particular, for c) and d) a careful evaluation 
of the cause of impaired organ function should be 
done, and in case of impaired renal function related 
to MM, the risk benefit of full-dose Melphalan 
should be considered. 
- Retrospective analysis of registry data showed an inferior 
OS in patients with HCT-CI 1-2 or >2, even if TRM at 1 year 
was equivalent in HCT-CI 0 or >2.41 
-Retrospective data showed also inferior OS in patients with 
R-MCI >4 vs 0-3.43 
 
- Reduced organ function can be related to MM, in 
particular in case of renal failure and reduced pulmonary 
function due to bone fractures (thoracic cage).  Achieving 
optimal disease control can improve organ function, in 






TABLE 5. ALLOGENEIC STEM CELL TRANSPLANT UPFRONT, DONOR VS NO-DONOR PROSPECTIVE TRIALS 
 
STUDY DESIGN PATIENTS MEDIAN FU PFS OS REF 
High-risk patients: 
                          BU-FLU-ATG allo-SCT 
Auto-SCT  













                         FLU-MEL allo-SCT 
Auto-SCT <CR  




Median not reached  
vs 
31 months (p=0.08) 
Median not reached  
vs 
58 months (p=0.9) 
69
 
                          2Gy TBI allo-SCT 
Auto-SCT 





Median 2.8 years 
vs 
2.4 years (p=0.005) 






                         2Gy TBI allo-SCT 
Auto-SCT 





At 3 years 43% 
vs 
46% (p=0.67) 





                         2Gy TBI allo-SCT 
Auto-SCT 





At 6 years 28% 
vs 
22% (p=0.19) 





                         FLU-TBI allo- SCT 
Auto-SCT  





At 8 years 22%  
vs 
12% (p=0.027) 






Abbreviations: SCT, stem cell transplant;  BU, busulfan; FLU, fludarabine; ATG, anti-thymocyte globuline; MEL, melphalan; TBI, total body irradiation; T, thalidomide; IFN, 
interferon.   
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TABLE 6. ALLOGENEIC STEM CELL TRANSPLANT AT RELAPSE 
STUDY DESIGN PATIENTS MEDIAN FU PFS OS REF 
Tandem auto-allo-SCT at 
first relapse, retrospective 23 27 months Median 36.8 months 61 at 2 years 
111
 
Allo- SCT RIC and MAC, 
retrospective 149 (121 RIC) 28.5 months 15% at 5 years 21% at 5 years 
112
 
Donor vs No-Donor,  
retrospective  
75 donor (68 allo-
SCT) 
94 no donor  
19 months 
Donor 51% at 2 years 
No donor 53% at 2 
years p=0.32 
Donor 42% at 2 years 




First Relapse post auto-
SCT:  




57 months from 
diagnosis 
Median 6 months 
Median 19 months 
p=0.56 
Median 19 months 




First relapse: MAC + 
lenalidomide maintenance 33 19 months 52% at 3 years 79% at 3 years 
88 
RIC in relapse post auto-
SCT, retrospective 413 - Median 9.6 months Median 24 months 
77
 
First Relapse post auto:  





6% at 3 years 
12% at 3 years 
p=0.038 
20% at 3 years 




Allo-SCT at relapse, 
retrospective  
639 before 2004 
2766 after 2004 
36 months 
25% at 5 years 
33% at 5 years 
p<0.0001 
10% at 5 years 




Allo-SCT at first relapse 
post auto-SCT, 
89 48 months 28% at 5 years 57% at 5 years 116 
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Abbreviations: SCT, stem cell transplant;  BU, busulfan; FLU, fludarabine; ATG, anti-thymocyte globuline; MEL, melphalan; TBI, total body irradiation; T, thalidomide; IFN, 
interferon. SCT, stem cell transplant;  RIC, reduced intensity conditioning; MAC myeloablative conditioning; EBMT, European Group for Blood and Marrow Transplantation;  
CIBMTR, Center for International Blood and Marrow Transplant Research 









Practical considerations Rationale for considerations 
At diagnosis - 
Clinical trial in young ultra high-risk/high-
risk patients  
 
Though results were discordant, prospective randomized studies (designed in the 
late ’90s – early 2000s) showed long-term disease control in subsets of patients 
who were not treated with new drugs; the combination of new drugs and graft-vs.-
myeloma may be of benefit in patients where prognosis remains currently very 
poor  
At relapse 2C 
Young patients with early relapse (18 
months) from first-line treatment 
with/without high-risk features   
Regardless of prognostic features, early relapse is overall associated with poor 
diagnosis. Retrospective studies support the existence of a potential benefit of 




post allografting - 
Clinical Trial  Maintenance therapy is currently part of prospective trials open to accrual. 







Figure 1. Recommended sequential treatment.  






Supplementary Table S1. GRADE recommendation for grading levels of evidence 
 
GRADE    
1 
Evidence strongly suggest that the benefit of 
the procedure out weights potential risks or 
risks of the procedures out weights potential 
benefit 
A 
Consistent evidence from systemic reviews 
of high-quality randomized studies or from 
high-quality randomized studies or from 
high-quality observational studies 
2 
Evidence suggests the benefit and risk of a 
procedure is finely balanced or uncertain 
B 
Evidence from randomized and 
observational studies with important 
methodological flaws 
  C 
Evidence from randomized and 
observational studies with major 






















Supplementary Table S2. Suggested Melphalan dose reduction in case of impaired organ function  
(Based on The Hematopoietic Cell Transplant-Comorbidity Index) 
 
Abbreviations: NYHA, New York Heart Association; DLCO, diffusion capacity of carbon monoxide; FEV1, forced expiratory volume; ULN, upper limit of normal; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase. 








NYHA II, coronary artery disease, congestive heart failure, 
arrhythmias 
40%-50% 
Pulmonary Function  DLCO / FEV1 >80% DLCO/FEV1 65-80% 
Hepatic Function 
Bilirubin < ULN 
AST/ALT < ULN 
Bilirubin > ULN-1.5 x ULN 
AST/ALT > ULN-2.5xULN 
